格隆汇1月29日｜Wedbush将微软公司目标价格从625美元下调至575美元，将Meta目标价格从880美元上 调至900美元。 ...

Core Viewpoint - Li Auto is undergoing a strategic recalibration by closing approximately 100 inefficient retail stores while simultaneously investing in AI and robotics, reflecting a dual approach of contraction and expansion in response to market challenges [2][4][12]. Group 1: Retail Strategy and Market Position - In early 2026, Li Auto plans to close around 100 low-efficiency retail stores, which are often located in prime areas of first and second-tier cities, as part of a broader strategy to adapt to changing consumer behaviors [4][27]. - The adjustment is not merely a cost-cutting measure but a strategic realignment following a year of declining performance, as consumers increasingly prefer shopping in multi-level commercial spaces rather than traditional car showrooms [6][29]. - In 2025, Li Auto set an ambitious sales target of 700,000 vehicles, which was later revised down to 640,000, with actual deliveries falling to approximately 406,343 vehicles, resulting in a loss of market leadership to competitors like Leap Motor [7][30]. Group 2: Financial Performance and Challenges - Li Auto's third-quarter revenue for 2025 was reported at 27.4 billion yuan, a year-on-year decline of 36.2%, with a net loss of 624 million yuan, marking the end of 11 consecutive profitable quarters [9][32]. - The decline in performance is attributed to setbacks in the pure electric vehicle market and increased competition from rivals employing aggressive pricing strategies [9][32]. - The company currently operates 548 retail centers, which incurs significant costs, prompting the need for channel optimization to improve overall efficiency [10][33]. Group 3: Future Strategy and AI Investment - Li Auto is shifting its focus towards AI technology and robotics, with plans to develop foundational models, chips, and intelligent systems, aiming to position itself among the top three global players in this field by 2028 [12][37]. - The company has expressed intentions to expand its brand identity from merely creating "mobile homes" to a broader vision encompassing "embodied intelligence," including the development of humanoid robots [14][37]. - Following the announcement of store closures and AI investments, Li Auto's stock rose by 4.9%, indicating positive market reception despite differing opinions among investors regarding the company's long-term competitiveness [16][39]. Group 4: Market Reactions and Analyst Ratings - Analysts are divided on Li Auto's long-term prospects, with optimistic views focusing on the potential of self-developed chips and AI models, while cautious perspectives highlight immediate operational pressures [18][42]. - Some analysts maintain a positive rating, projecting a target price of 100 HKD for the stock, while others have downgraded their ratings due to concerns over short-term challenges, setting a target price of 17.5 USD [18][43].

长风药业(02652)发布公告，于2026年1月29日斥资41.08万港元回购1.15万股。 ...

格隆汇1月29日丨环康集团(08169.HK)公告，截至2025年10月31日止年度，收益减少约4%至9061万港 元。公司拥有人应占亏损约为286.8万港元(2024年：180.6万港元)。截至2025年10月31日止年度，每股 基本及摊薄亏损为0.44港仙(2024年：0.28港仙)。 ...

环康集团(08169)公布截至2025年10月31日止年度业绩，收益减少约4%至9061万港元，公司拥有人应占 亏损约为286.8万港元，同比扩大58.8%;每股亏损0.44港仙。 ...

智通财经APP讯，环康集团(08169)公布截至2025年10月31日止年度业绩，收益减少约4%至9061万港 元，公司拥有人应占亏损约为286.8万港元，同比扩大58.8%;每股亏损0.44港仙。 ...

1. 主营业务改善：受益于智能手机摄像头规格高端化，凭借技术布局和产品迭代优势，手机镜头和 摄像模组平均售价提升，毛利率改善 2. 投资收益：转让若干附属公司全部股权换取歌尔光学科技股权，产生投资收益约9.19亿元人民币 以上数据基于未经审计管理账目的初步评估 2025年度经审计综合业绩预计于2026年3月底前公布 舜宇光学科技（02382.HK）正面盈利预告要点解读核心要点 其他说明： 预计2025年度归母净利润约45.89亿-47.24亿元人民币，同比增长70%-75% 2024年度归母净利润为26.99亿元人民币 业绩预告： 增长驱动因素： ...

专题：为中国经济点赞——企业家之夜2025盛典 "为中国经济点赞——企业家之夜"于1月29日在北京举行。珍酒李渡集团、华致酒行董事长 吴向东出席 接受致敬。绿地集团董事长、总裁张玉良，全聚德集团党委书记、董事、总经理周延龙，联合国前副秘 书长金垣洙为其见证荣誉。 致敬词： 他是传统酿造精神与现代商业智慧融合的践行者，始终致力于推动中国酒业发展。酒业深度调整之际， 他坚守"长期主义"，推出战略级产品"大珍·珍酒"和"牛市啤酒"，开创全新商业模式。他更以躬身践行的 姿态，打造冠绝酒业群雄的超级IP。他用行动证明，在这个追求速度的时代，沉心打磨品质，才是最持 久、最珍贵的竞争力。 金垣洙回忆了一年前赴珍酒李渡的经历，他表示 ，珍酒酿造工艺独特、管理科学规范、产能规模宏 大。这杯酒，是匠心、科技与自然共酿的杰作。 张玉良表示，希望珍酒李渡在未来，无论是风雨还是阳光，都能持续地为国家和白酒产业、消费者提供 更多优质的产品和服务。 周延龙表示，作为实体经济的代表，甚至是传统服务行业实体经济的代表，让我们一起努力，赢得更多 的消费者、更多的媒体为实体经济点赞，为中国经济点赞，相信在新的消费模式之下，我们一定会有更 好的未来 ...

Core Insights - The article highlights the inclusion of Ivonescimab, a PD-1/VEGF bispecific antibody developed by Kangfang Biopharma, in the FirstWord Pharma's "Spotlight On: The drugs that will shape 2026" list, marking it as the only drug from a Chinese innovative pharmaceutical company [1][2] Company Overview - Kangfang Biopharma, established in 2012 in Zhongshan, focuses on addressing unmet clinical needs through technological innovation and has developed over 50 innovative drug candidates targeting major diseases [4] - The company is the only pharmaceutical firm globally with two tumor immune bispecific antibody drugs, with seven new drugs already commercialized and four additional indications under review [4] Drug Development and Market Potential - Ivonescimab is set to receive approval from the National Medical Products Administration of China in May 2024 for treating locally advanced or metastatic non-small cell lung cancer (nsq-NSCLC) after progression on EGFR-TKI therapy [2] - The drug has been recognized for its clinical value and commercial potential, being included in the national medical insurance catalog in November 2024 [2] - The global development of Ivonescimab, in collaboration with Summit Therapeutics, positions it as a leader in the PD-(L)1/VEGF bispecific antibody space, with significant attention on its potential in broader clinical applications beyond second-line NSCLC [3] Industry Context - The trend of developing PD-(L)1/VEGF bispecific antibodies is largely driven by China, with clinical studies indicating enhanced efficacy in treating non-small cell lung cancer compared to PD-1 monotherapy [3] - The biopharmaceutical industry in Zhongshan is recognized as a key sector, with the city expanding its health base and establishing a comprehensive support system for biopharmaceutical innovation, including a 10 billion yuan angel fund [4][5]

智通财经APP讯，石药集团(01093)发布公告，集团开发的SYS6055注射液已获得中华人民共和国国家药 品监督管理局(NMPA)批准，可在中国开展临床试验。 本次获批的临床适应症为复发╱难治侵袭性B细胞淋巴瘤。此外，该产品亦具备用于治疗其他CD19阳 性的B细胞恶性肿瘤和自身免疫病的潜力，具有较高的临床开发价值。 该产品为国内首款获批临床的体内CAR-T产品，通过慢病毒载体在体内直接生成靶向CD19 的CAR-T细 胞，可特异性识别和清除靶细胞，从而达到治疗目的。与传统CAR-T产品相比，该产品在成本、可及性 和即时性等方面具备潜在优势。临床前研究显示，该产品可在体内特异性生成CAR-T细胞，具有显着的 抑瘤效果与良好的安全性，并具有成本和时间优势，有望为B淋巴细胞肿瘤患者提供更好的治疗选择。 ...